OraSure Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OSUR research report →
Range $7 – $7
Price Chart
About the company
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions.
- CEO
- Carrie Eglinton Manner
- IPO
- 1986
- Employees
- 500
- HQ
- Bethlehem, PA, US
Get TickerSpark's AI analysis on OSUR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $238.90M
- P/E
- -5.01
- PEG
- 3.84
- P/S
- 2.06
- P/B
- 0.78
- EV/EBITDA
- -2.54
- Div Yield
- 0.00%
- Gross Margin
- 41.91%
- Op Margin
- -40.90%
- Net Margin
- -41.73%
- ROE
- -15.17%
- ROIC
- -14.56%
Latest fiscal year · YoY change
- Revenue
- $115.02M-38.1%
- Gross Profit
- $48.20M-36.8%
- Op Income
- $-68,124,000
- Net Income
- $-68,731,000-252.5%
- EPS
- $-0.94-261.5%
- OCF Growth
- -279.1%
- FCF Growth
- -325.7%
- 52W High
- $4.58
- 52W Low
- $2.08
- 50D MA
- $3.74
- 200D MA
- $3.57
- Beta
- 1.06
- RSI (14)
- 48
- Avg Volume
- 575.66K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
OraSure posted a solid Q3 return to growth, with revenue up 14%, gross margin expansion, and a more conservative 2027 cash-flow breakeven target after rethinking the timing of new product catalysts.· November 9, 2026
- Q3 revenue was $30.9 million, up 14% year over year and about 1% sequentially, as the company returned to growth.
- Gross margin improved meaningfully, with GAAP gross margin at 45.2% versus 43.5% last year; non-GAAP gross margin was 45.9%.
- International diagnostics improved on higher HIV revenue, better HCV performance, and continued Sickle SCAN growth; Sample Management Solutions grew 21% year over year.
- Management said Ebola 2.0 initial commercial orders were fulfilled, but broader adoption likely depends on the BRIDGE Access Study and local contracting pathways.
- The company now expects cash flow from operations breakeven in the second half of 2027, later than the prior plan that had implied entry into 2027.
Total revenue was $30.9 million in Q3, up 14% year over year and approximately 1% sequentially. Diagnostic products revenue was $16.8 million, up 16% year over year, and Sample Management Solutions revenue was $12.5 million, up 21% year over year. GAAP gross margin increased to 45.2% from 43.5% a year ago; non-GAAP gross margin rose to 45.9% from 44.2%. GAAP operating loss was $13 million and non-GAAP operating loss was $10.2 million. The company ended the quarter with $148.2 million in cash and cash equivalents and no debt, and operating cash flow was negative $10.9 million. For Q4, management expects revenue of $30 million to $32 million, full-year revenue of $119.5 million to $121.5 million, and gross margin similar to or slightly below Q3. Management now expects cash flow from operations breakeven in the second half of 2027, and said full-year revenue growth should accelerate in 2027 versus 2026.
Carrie Eglinton Manner said Q3 showed the company’s strategy working: simplified portfolio, stronger manufacturing, cost discipline, and innovation are driving both revenue and margin improvement. She highlighted international diagnostics as a key growth engine, pointing to Ebola 2.0 readiness, local assembly in Uganda, a planned expansion into Nigeria, and early momentum in sickle cell testing. Her tone was upbeat but cautious on timing, especially around Ebola adoption and the regulatory path for InteliQuick CT/NG.
Ken McGrath detailed the quarter’s financial progress: revenue of $30.9 million, gross margin of 45.2% GAAP and 45.9% non-GAAP, and lower operating expenses, including R&D of $7.6 million, sales and marketing of $6.6 million, and G&A of $12 million. He noted Q3 operating leverage from improved overhead absorption and said the company had $148.2 million in cash, no debt, and negative $10.9 million in operating cash flow. On guidance, he said Q4 revenue should be $30 million to $32 million and gross margin should be similar to or slightly below Q3, while the company now expects cash flow breakeven in the second half of 2027 because the timing of growth drivers has shifted.
Analysts focused on the CT/NG resubmission timeline, the assumptions behind the 2027 cash-flow target, and whether Q4 guidance implies any revenue pull-forward. Management said CT/NG is in the pre-sub process with multiple possible regulatory paths, but timing remains TBD; they also said Q4 OpEx should be similar to Q3 overall. On Ebola, management said contracting is still waiting on catalyst events such as the BRIDGE Access Study, but they expect more clarity before year-end and said the company is well positioned to serve regional needs.
The bullish case is that OraSure is showing real operating improvement: revenue growth resumed, gross margins expanded, and expenses came down. Management also pointed to multiple growth avenues still in motion, including HIV, HCV, Sickle SCAN, Ebola 2.0, and Colli-Pee Dx, with international localization and partnerships potentially broadening adoption over time.
The main risk is timing: several hoped-for catalysts are still uncertain, including Ebola contracting, broader adoption of Ebola 2.0, and the regulatory path for CT/NG. Management pushed out cash-flow breakeven to the second half of 2027, which signals that some expected contributions will take longer than previously assumed, and they said quarterly revenue will continue to be affected by order timing and product mix.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 82.6%
- Shares Outstanding
- 69.05M
- Float Shares
- 57.01M
of shares held by institutions
156 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for OSUR, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 6.07M | ▼ 183.06K |
| Vanguard Group Inc | 4.10M | ▼ 31.51K |
| Neuberger Berman Group LLC | 4.09M | ▼ 595.56K |
| Yorkville Advisors Global, LP | 3.93M | ▲ 3.93M |
| Altai Capital Management, L.P. | 3.61M | 0 |
| Private Management Group Inc | 3.18M | ▼ 617.67K |
| Vanguard Capital Management LLC | 2.90M | ▼ 118.69K |
| Systematic Financial Management LP | 2.86M | ▲ 377.49K |
| Dimensional Fund Advisors LP | 2.26M | ▼ 85.37K |
| Acadian Asset Management LLC | 2.02M | 0 |
| Renaissance Technologies LLC | 1.95M | ▼ 60.70K |
| Gagnon Securities LLC | 1.83M | ▲ 234.46K |
Held by 172 ETFs
Biggest fund positions in OSUR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 29, 26 | Boyd Steven Kyle | other | 4,797 |
| Sep 6, 26 | Kenny John P. | other | 5,116 |
| Jun 26, 26 | Boyd Steven Kyle | other | 3,666 |
| Jun 3, 26 | McMahon Robert W. | other | 46,106 |
| Jun 3, 26 | Gagliano Nancy J | other | 46,106 |
| Jun 3, 26 | Marmora Lelio | other | 46,106 |
| Jun 3, 26 | Kenny John P. | other | 46,106 |
| Jun 3, 26 | Bertrand John D. | other | 46,106 |
| Jun 3, 26 | Boyd Steven Kyle | other | 46,106 |
| May 14, 26 | Boyd Steven Kyle | buy | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OSUR coverage
Recent articles, reports, and earnings notes.
No research on OSUR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OSUR report →OraSure Technologies, Inc. (OSUR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
OraSure Technologies Q3 Earnings Call Highlights
marketbeat.com · Nov 9
OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion
globenewswire.com · Nov 9
OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care
globenewswire.com · Nov 2
OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th
globenewswire.com · Oct 26
OraSure Technologies (NASDAQ:OSUR) Stock Crosses Above 200-Day Moving Average – Here’s Why
defenseworld.net · Oct 15
Contrasting Establishment Labs (NASDAQ:ESTA) & OraSure Technologies (NASDAQ:OSUR)
defenseworld.net · Oct 7
OraSure Technologies (NASDAQ:OSUR) Share Price Crosses Above 200 Day Moving Average – Here’s What Happened
defenseworld.net · Oct 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.